ArticleMolecular medicine reports2018

Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells.

Lifang Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.